Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%

Overview

• U.S. medical technology firm's fiscal Q3 revenue rose 46% yr/yr, driven by cartridge sales

• Gross profit margin improved to 50.5% from 46.8% a year ago

• Company reported Q3 net loss per share of $1.80

Outlook

• Company says it is progressing toward entry into the U.S. drug screening market

• Intelligent Bio Solutions expects continued growth through the remainder of fiscal 2026

• Company sees expanding gross margins and recurring revenue as key drivers going forward

Result Drivers

• CARTRIDGE SALES GROWTH - Q3 cartridge revenue rose 59% yr/yr and accounted for 66% of sales, reflecting recurring demand from the installed base

• GROSS MARGIN EXPANSION - Gross profit margin improved to 50.5% in Q3, driven by operational efficiencies, higher sales volumes, and new manufacturing partnership

• OTHER SALES INCREASE - Q3 'other' sales rose 80% yr/yr, signaling a broadening product ecosystem and revenue diversification

Company press release: ID:nGNX2jp4gQ

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.